“This designation recognizes Dr. Andrew Maes as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
March 12, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Andrew Maes, Do, Thedacare in Berlin, WI has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Maes has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Andrew Maes as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

iJoin MAP makes it easy to help plan participants take action and get on track for long term success.

SCOTTSDALE, Ariz. (PRWEB)
March 11, 2020

The new iJoin Managed Account Program (MAP) provides financial advisors an evolved, “manage it for me” investing option for retirement plan participants. Founded on liability-driven investing principles, iJoin’s goal-based MAP personalizes recommendations based on each person’s age, income, savings and dozens of other known data points to achieve retirement income sufficiency.

At the discretion of the plan advisor and plan sponsor, iJoin‘s MAP may be implemented as the plan’s Qualified Default Investment Alternative (QDIA), providing ERISA 3(38) fiduciary protection to both the plan and participants. In doing so, the plan sponsor simultaneously obtains safe harbor protection by conducting a re-enrollment event.

iJoin has evolved the approach to modeling goal completion by assigning, continuously monitoring, and updating the investment strategy for each investor based on market performance, accumulated savings, contribution rates, and other factors. The approach is designed to accommodate a retirement plan’s existing investment lineup and 3(38) Investment Manager. The core logic may be applied to investment lineups seeking to achieve a Target Rate of Return or an Expected Rate of Return.

The program applies a liability-driven investment methodology in modeling each person’s retirement funding need, defined as the cost of an annuity that would yield the desired retirement income. iJoin’s calculations use market annuity prices to fund inflation-adjusted, lifetime retirement income. The calculator also incorporates critical external income sources like Social Security, outside pensions, and other savings.

Recordkeeping platform integration provides access to essential data on plan limits, matching contributions, and auto-increase features. iJoin actively considers these variables to help participants maximize their savings potential. Projections based on broader, more comprehensive data lead to greater client confidence in the process and in their own savings path. This supports the role of the financial advisor as their guide.

iJoin MAP makes it easy to help plan participants take action and get on track for long term success.

About LDI-MAP, LLC (dba iJoin)

The iJoin team is committed to personalizing retirement success™ and making it easy for millions of savers to get on a path to better retirement outcomes. As a financial technology partner to the retirement plan industry, iJoin’s goal-based retirement plan enrollment experience helps people immediately understand their retirement funding need and encourages action to get on track. iJoin supports financial advisors and recordkeepers with actionable data and tools to more effectively engage both employers and their employees. LDI-MAP (d.b.a. iJoin) is a registered investment advisor with the State of Arizona – 14646 N. Kierland Boulevard, Suite 125 Scottsdale, AZ 85254. Learn more at ijoinsuccess.com.

Share article on social media or email:

By supplementing a balanced diet with proper vitamin intake, probiotics and regular grooming, Irish dogs can combat these predispositions and live long, healthy and prosperous lives.

With St. Patrick’s Day quickly approaching, we want to bring more than luck to these pet parents. We want to give them awareness of the specific needs of Irish breeds, so they can enjoy a long and healthy life together.

GAITHERSBURG, Md. (PRWEB)
March 11, 2020

This St. Patrick’s Day, RestoraPet, a pet health supplement that restores wellness in older pets experiencing age-related decline and boosts the health and well-being of younger pets, advises owners of native Irish dog breeds to look out for specific health concerns from hip dysplasia to cataracts, and has provided pet lovers with the natural tools they need to combat them.

Among the most common health issues faced by Irish dog breeds is hip dysplasia. This is especially seen in breeds such as Irish Glen of Imaal Terriers, Irish Soft Coated Wheaten Terriers, Irish Wolfhounds, Irish Kerry Blue Terriers, and Irish Water Spaniels. In addition to hip problems, Irish dog breeds have been known to be prone to digestive issues such as bloating, hair loss and cataracts. Luckily, hope exists for pet lovers who select natural wellness options. By supplementing a balanced diet with proper vitamin intake, probiotics and regular grooming, Irish dogs can combat these predispositions and live long, healthy and prosperous lives.

“We’re more than pet owners. We are pet parents,” says RestoraPet CEO, Brian Larsen, “When pets develop health problems, many pet parents look to natural remedies before they give their pets heavier drugs and surgery. With St. Patrick’s Day quickly approaching, we want to bring more than luck to these pet parents. We want to give them awareness of the specific needs of Irish breeds, so they can enjoy a long and healthy life together.”

Specific recommendations for avoiding health concerns associated with Irish dog breeds include:

• 
  Proper Vitamin Intake – A top tactic for avoiding several health concerns among Irish dog breeds is ensuring these dogs receive a proper balance of vitamins. Vitamins A, C, E, and Coenzyme Q10, are essential to ocular, digestive and muscular health.
• Prioritizing Digestive Health – Adding probiotics into an Irish dog’s diet is a safe and effective way for pet parents to aid in improving their dog’s gastrointestinal health, a prominent concern for owners of Irish Setters. Putting a priority on digestive health has also shown to be effective in breeds such as Irish Water Spaniels, who can develop immune deficiencies which can be further combated with a whole food organic diet, massages, turmeric, Omega-3, vitamin E, selenium, vitamin C, probiotics, hydrotherapy, and acupuncture.
• Proper Grooming – Hair loss and follicle tumors are often listed as concerns for Irish Water Spaniels and Kerry Blue Terriers. Pet owners can simply combat hair loss by incorporating humidity, apple cider vinegar, regular brushing, lemon juice, topical olive oil, and omega biotics into their pet’s regular grooming routines.

A Truly Comprehensive Solution

RestoraPet’s breakthrough blend of all-natural supplements and 12 antioxidants is designed to heal the cellar degeneration associated with aging from the first administered dose and is a truly complete solution for fighting common health concerns associated with Irish dog breeds. The organic, vegetarian & GMO-free formula includes 50 milligrams of Vitalitrol®, a proprietary carbon-based antioxidant that begins working from the first administered dose to rehabilitate and protect every cell type in your pet’s body, and actively combats inflammation with Omega3 and Omega-6, boosts immunity and fights infections with complete vitamin E, improves mobility, increases muscle strength, elevates energy levels, eases discomfort, improves mood, increases trainability, supports organ health (especially heart and kidney), improves skin and coat health with lutein and zeaxanthin and supports happier, healthier pets. RestoraPet is also the only anti-aging supplement offered in bacon and beef flavors to satisfy even the pickiest of pets.

ABOUT RESTORAPET:

RestoraPet® is the most effective line of pet supplements ever created. Made with the perfect blend of love and science, RestoraPet® restores wellness in older pets experiencing age-related decline and boosts the health and well-being of younger pets. First introduced to the market in 2014, RestoraPet® products are now used by tens of thousands of pets (especially dogs, cats, and horses) in more than 100 countries worldwide. RestoraPet® contains a remarkable, carbon-based “super antioxidant” that scientists created called Vitalitrol®, and begins working from the very first administered dose to rehabilitate and protect almost every type of cell in a pet’s body. Learn more at restorapet.com

Media Contact:

April White

Trust Relations

restorapet@trustrelations.agency

323-216-8589

Share article on social media or email: